- Organizations: Orasis Pharmaceuticals
Products
Orasis's QLOSI for presbyopia launches in the US
Pilocarpine 0.4% provides patients with flexible dosing for up to 8 hours of clear near vision; prescription-based drops are available through two pharmacy partners.Products
Orasis secures financing to support US commercial launch of Qlosi
With $78 million in Series D financing, the preservative-free pilocarpine solution is one step closer to availability.
Products
FDA approves Orasis's QLOSI for presbyopia
The preservative-free, low-dose eye drop will be commercially available in 2024.
Pipeline
FDA accepts Orasis NDA for CSF-1 to treat presbyopia
A PDUFA target action date has been set for later this fall.
Pipeline
Orasis Pharmaceuticals submits NDA for CSF-1 for the treatment of presbyopia
Could a new presbyopia drug be coming?
Archives